Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis

Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.

Atopic dermatitis
Arcutis moves toward adding AD to the Zoryve label • Source: Shutterstock

With success in a second Phase III trial of its topical formulation of roflumilast in atopic dermatitis, Arcutis Biotherapeutics, Inc. moved closer to seeking a supplemental approval of Zoryve (roflumilast) in AD, which analysts said would be an even bigger market opportunity than the drug’s initial indication in plaque psoriasis.

More from Clinical Trials

More from R&D

AbbVie On A STEAP Learning Curve In ADCs

 

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials

 

After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.